Call Us: 1 (800) 647 6100
6900 Kingspointe Pkwy, Orlando, FL 32819, US
Open in Google Maps
6900 Kingspointe Pkwy, Orlando, FL 32819, US
People First Culture
Nov. 7, 2018—After hosting 20 successful invitation-only XYMOGEN XPERIENCE events all over the country, XYMOGEN will usher in a new way of offering integrative medicine education and networking opportunities.
XYMOGEN is sad to announce that founding board member, Eve Plews, passed away Saturday, September 1, 2018
XYMOGEN® does it again! For two months in a row, the company has beaten its own sales records. May’s sales topped $11 million, the highest in the company’s more than 25-year history, compared to April’s already high-performing sales at $10 million. May also saw a new daily sales record of over $500,000 a day, which is a 30 percent increase over 2017’s daily sales.
XYMOGEN® is proud to announce that April was the company’s highest-grossing sales month in its 25+ year history, garnering a total of $10 million in sales.
January 29, 2018—XYMOGEN®, the leader in exclusive and proprietary professional nutraceutical formulas, is proud to announce that it surpassed the $100 million milestone in revenues for fiscal year 2017.
On Oct. 12, 2017, XYMOGEN was honored with the prestigious 2017 Manufacturers Association of Central Florida’s (MACF) Award of Excellence for Manufacturer of the Year in the large manufacturer size category.
Orlando-based health sciences company XYMOGEN has recently been recognized for the tenth time on Inc. Magazine’s Inc. 5000 list as one of the fastest growing and best-run private companies in the nation
XYMOGEN is way ahead of the supplements transparency curve. Recently, Amazon Elements, the mega internet retailer’s private label brand, has included four dietary supplements, in an effort, it states, to bring more transparency and safety to these products. As the only exclusive practitioner-channel supplements formula company, XYMOGEN has been offering this transparency to its customers for years.
XYMOGEN, in partnership with FON Consulting, publishes a chronicle of the dramatic rise and influence of integrative healthcare.
ORLANDO, Fla. — October 4, 2016 — XYMOGEN® rocks the nutraceutical industry yet again with the introduction of its patented and exclusive MonoPure™ line of omega-3 EPA + DHA products. What makes MonoPure™ so different from other omega-3 EPA + DHA products is that it delivers an easy to digest highly concentrated omega-3 fish oil, which when studied clinically was shown to be three times more absorbable* than ethyl ester (EE) fish oil.
ORLANDO, Fla. (September 27, 2016)—XYMOGEN is proud to announce that it has been chosen by Mount Sinai Medical Center of Florida and the Duke Clinical Research Institute to manufacture and supply the oral vitamin and mineral preparations that will be tested in the second Trial to Assess Chelation Therapy (TACT2), a $37M federally sponsored clinical trial.
Orlando, FL. – September 22, 2016 – Orlando-based health sciences company XYMOGEN has recently been recognized for the ninth time on Inc. Magazine’s Inc. 5000 list as one of the fastest growing and best-run private companies in the nation.
XYMOGEN, a leading functional medicine manufacturer, is one of several companies that have purposely sidestepped doing business on the mega-Internet sales site Amazon.com. To highlight this turn of events, Birkenstock, the icon of environmental consciousness and centuries of shoemaking expertise, recently stated that its products will no longer be sold on Amazon.com.
July 26, 2018 is circled on the XYMOGEN calendar. On or before this date, we—like every food and supplement manufacturer—will have completed the task of modifying each and every XYMOGEN formula label to comply with the new rules set forth by the US Food and Drug Administration (FDA) in the Federal Register under "Food Labeling: Revision of the Nutrition and Supplement Facts Labels." These rules took effect on July 26, 2016.
Read the following article from Nutraceuticals World for more information from Brian Blackburn as to why XYMOGEN is opposed to online retail sales of professional formulas.
XaQuil® XR the newest product from XYMOGEN's medical food* line, PharmaceutiX® , is one of the most exciting products of the year, and the company is racking up the awards to prove it.
With new understanding, research and testing comes new breakthroughs*. That's why we are letting you know we will no longer be carrying MaX Heart™.
Gnosis S.p.A. April 2016 Newsletter
Quatrefolic® in partnership with XYMOGEN® is short-listed for NutraIngredients Awards 2016!
The partnership between Gnosis and the US nutraceutical producer XYMOGEN® is proving innovative! XYMOGEN’s XaQuil®XR, finished oral dose product containing Gnosis’ Quatrefolic®, has been selected as a finalist of NutraIngredients Awards 2016 for the Finished Product of the Year – Medical Food category.
ORLANDO, Fla. – DAY, 24, February 2016 — XYMOGEN, the Orlando-based health sciences company, has earned Australia’s prestigious certification from the Therapeutic Goods Administration (TGA), that country’s equivalent to the U.S. Federal Drug Administration.
Brian Blackburn, CEO of XYMOGEN named one of Orlando Business Journal's 2015 CEO of the Year Honorees.
ORLANDO, Fla. -- February 26, 2015 -- Orlando-based health sciences company XYMOGEN has announced it surpassed the Seven Million Dollar Month Revenue Milestone for January-2015. This represents the third consecutive January in which the company surpassed a Million-Dollar Milestone, reaching $5 million and $6 million in 2013 and 2014, respectively.
I am writing you in response to the New York AG investigation of herbal supplements sold at retail outlets (GNC, Walgreens, Walmart, and Target).
Orlando-based health sciences company XYMOGEN announced today that it has been recognized for the seventh time on Inc. Magazine’s Inc. 5000 list as one of the fastest growing and best run private companies in the nation.
Orlando-based health-sciences company XYMOGEN announced that ALAmax Protect™, the latest formula in the company’s line of professional formulas to support cardio metabolic health, is now available.
Once again, the major media outlets are making a major splash with the negative news about niacin based on the HPS2-THRIVE study – first announced in March of 2013, and now again with the full publication of the study in the New England Journal of Medicine.
Join our mailing list.
Interested in receiving special offers, access to exclusive webinars, seminars, up-to-date industry news, and so much more? Sign up for our FREE newsletter and get started today!
BONUS: As a XYMOGEN Insider, you will also get a FREE digital copy of The Rise of Integrative Health & Medicine—The Milestones: 1963–Present by Glenn Sabin and Taylor Walsh.
We at XYMOGEN, are committed to respecting your online privacy and recognize your need for appropriate protection and management of any personally identifiable information ("Personal Information") you share with us.
Personal Information means any information that may be used to identify an individual, including, but not limited to, a first and last name, a home or other physical address and an email address or other contact information, whether at work or at home. In general, you can visit XYMOGEN's Web pages without telling us who you are or revealing any Personal Information about yourself.
If you choose to provide us with your Personal Information on the Web, we may transfer that Information within XYMOGEN or to XYMOGEN's third-party service providers, across borders, and from your country or jurisdiction to other countries or jurisdictions around the world.
Where XYMOGEN collects Personal Information on the web, we intend to post a purpose statement that explains why Personal Information will be collected and whether we plan to share such Personal Information outside of XYMOGEN or those working on XYMOGEN's behalf. XYMOGEN does not intend to transfer Personal Information without your consent to third parties who are not bound to act on XYMOGEN's behalf unless such transfer is legally required.
You may choose whether or not to provide Personal Information to XYMOGEN. The notice we intend to provide where XYMOGEN collects Personal Information on the Web should help you to make this choice. If you choose not to provide the Personal Information we request, you can still visit most of XYMOGEN's Web sites, but you may be unable to access certain options, offers, and services that involve our interaction with you.
If you chose to have a relationship with XYMOGEN, such as a contractual or other business relationship or partnership, we will naturally continue to contact you in connection with that business relationship.
Wherever your Personal Information may be held within XYMOGEN or on its behalf, we intend to take reasonable and appropriate steps to protect the Personal Information that you share with us from unauthorized access or disclosure.
To the extent that you do provide us with Personal Information, XYMOGEN wishes to maintain accurate Personal Information. Where we collect Personal Information from you on the Web, our goal is to provide a means of contacting XYMOGEN should you need to update or correct that Information. If for any reason those means are unavailable or inaccessible, you may send updates and corrections about your Personal Information to privacy@XYMOGEN.com and we will make reasonable efforts to incorporate the changes in your Personal Information that we hold as soon as practicable.
Third parties provide certain services available on XYMOGEN.com on XYMOGEN's behalf. XYMOGEN may provide information, including Personal Information, that XYMOGEN collects on the Web to third-party service providers to help us deliver programs, products, information, and services. Service providers are also an important means by which XYMOGEN maintains its Web site and mailing lists. XYMOGEN will take reasonable steps to ensure that these third-party service providers are obligated to protect Personal Information on XYMOGEN's behalf.
XYMOGEN does not intend to transfer Personal Information without your consent to third parties who are not bound to act on XYMOGEN's behalf unless such transfer is legally required. Similarly, it is against XYMOGEN's policy to sell Personal Information collected online without consent.
XYMOGEN.com is not structured to attract children. Accordingly, we do not intend to collect Personal Information from anyone we know to be under 13 years of age.
We are committed to privacy and, through our membership in the Online Privacy Alliance, are actively involved in and support current industry initiatives to preserve individual privacy rights on the Internet. Protecting your privacy online is an evolving area, and XYMOGEN's Web sites are constantly evolving to meet these demands.
*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.